FWBI - First Wave BioPharma Signs Exclusive Global License Agreement with Sanofi for Capeserod from Sanofi

2023-09-14 09:07:26 ET

(24/7 MARKET NEWS) – First Wave BioPharma, Inc. (NASDAQ:FWBI) stated, this morning, that it signed an agreement to license Sanofi’s (NASDAQ:SNY) selective 5-HT4 receptor partial agonist, Capeserod, which First Wave will repurpose and develop for gastrointestinal (GI) indications.

First Wave BioPharma is trading at $0.798, up $0.3629 (+83.41%), on 14.84M premarket shares traded.

Its 52-week range is $0.2733 to $16.38. Today’s action looks like it blow through its September 5th move and may even challenge the $1.50 level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a …

The post First Wave BioPharma Signs Exclusive Global License Agreement with Sanofi for Capeserod from Sanofi appeared first on 24/7 Market News .

For further details see: